Rigel Pharmaceuticals (RIGL) Tops Q4 EPS by 1354c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $50.53 -1.52%
Revenue Growth %: +15.2%
Financial Fact:
Interest income: 110K
Today's EPS Names:
LTBR, AES, SYRS, More
Revenue Growth %: +15.2%
Financial Fact:
Interest income: 110K
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Rigel Pharmaceuticals (NASDAQ: RIGL) reported Q4 EPS of $13.54. Revenue for the quarter came in at $69.8 million.
For earnings history and earnings-related data on Rigel Pharmaceuticals (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
- TETRA Technologies (TTI) Tops Q3 EPS by 1c, Beats on Revenue
- Hillman Solutions (HLMN) Tops Q3 EPS by 1c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
